Verition Fund Management
GYRE icon

Verition Fund Management’s Gyre Therapeutics GYRE Stock Holding History

Verition Fund Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,345
Closed -$98.1K – 3858
2025
Q2 		$98.1K Buy
+13,345
New +$116K ﹤0.01% 3488
2021
Q3 		– Sell
-51,613
Closed -$1.68M – 2072
2021
Q2 		$1.68M Buy
51,613
+14,039
+37% +$482K 0.02% 599
2021
Q1 		$1.42M Sell
37,574
-2,677
-7% -$122K 0.02% 507
2020
Q4 		$1.91M Buy
+40,251
New +$1.74M 0.02% 384

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Verition Fund Management's GYRE Position: Q3 2025 in Review

Verition Fund Management sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 13,345 shares — an estimated $98.1K sold.

Verition Fund Management first reported a position in GYRE in Q4 2020 and held it in 4 quarters. The position peaked at $1.91M in Q4 2020. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

  • Verition Fund Management reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 13,345 Gyre Therapeutics shares in Q3 2025, an estimated $98.1K.
  • Verition Fund Management first reported a position in Gyre Therapeutics in Q4 2020 and held it in 4 quarters.
  • Verition Fund Management's Gyre Therapeutics position peaked at $1.91M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.